ABT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Abbott Laboratories (ABT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive long-term prospects, recent financial performance, insider sentiment, and congress trading data suggest caution. The stock might be better evaluated after the first half of 2026 when the company's Nutrition segment stabilizes and the Exact Sciences acquisition begins to show results.
The MACD is positive and expanding, indicating bullish momentum. RSI is at 72.751, which is neutral but approaching overbought levels. The stock is trading near its resistance level (R1: 115.805), suggesting limited short-term upside. Moving averages are converging, showing no clear trend.
Abbott has increased its dividend for 54 consecutive years, appealing to long-term investors.
The $23 billion acquisition of Exact Sciences is expected to strengthen its diagnostics and cancer testing market position.
The company reported a 5.7% revenue increase for 2025, driven by strong performance in pharmaceuticals, nutrition, and medical devices.
Q4 financials showed a significant drop in net income (-80.76% YoY) and EPS (-80.72% YoY), raising concerns about profitability.
Analysts have lowered price targets across the board due to challenges in the Nutrition and Diagnostics segments, with a cautious outlook for the first half of
Congress trading data shows 4 sale transactions and no purchases, indicating caution from influential figures.
In Q4 2025, revenue increased by 4.42% YoY to $11.46 billion, but net income dropped by 80.76% YoY to $1.776 billion. EPS also declined by 80.72% YoY to $1.02. Gross margin improved to 53.36%, up 4.75% YoY, but the overall financial performance was weak due to setbacks in the Nutrition segment.
Analysts have a mixed to cautious outlook on ABT. While many maintain Buy or Overweight ratings, price targets have been lowered across the board, reflecting challenges in the company's Nutrition and Diagnostics segments. Analysts expect stabilization and growth in the second half of 2026, but the near-term outlook remains subdued.
